Tests with a new compound (Praziquantel) against Diphyllobothrium latum.
Praziquantel (Droncit) is a new anthelminthic agent with a strikingly wide therapeutic index. The efficiency of the drug against Diphyllobothrium latum was tested in vivo and in vitro. With a drug dose of 50 mg/kg, artificially infected hamsters were completely cured. The threshold value of the active dose was between 2-5 and 10-0 mg/kg. Clinical trials with Praziquantel against human diphyllobothriasis show great promise, all of ten patients treated with 25-0 mg/kg of the drug being cured. Praziquantel had little effect on larval or adult diphyllobothriids in vitro.
D000818:Animals; D000923:Anticestodal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006224:Cricetinae; D004169:Diphyllobothriasis / Q000188:drug therapy*; D004170:Diphyllobothrium / Q000187:drug effects; D006801:Humans; D007546:Isoquinolines / Q000494:pharmacology / Q000627:therapeutic use*; D008647:Mesocricetus
D000923:Anticestodal Agents; D007546:Isoquinolines